NCT01085162View on ClinicalTrials.gov

A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Coronary Artery Disease (CAD)
Interventions
DRUG

BMS747158

BMS747158 is a novel PET MPI agent labeled with Fluorine-18.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, S. Mark Taper Foundation Imaging Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Lantheus Medical Imaging

INDUSTRY